News & Updates

Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

01/13/2021

Excerpt from the Press Release: Burlingame, CA, and Chicago, IL – January 10, 2021 – Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, and EVERSANA, a pioneer of next-generation services to the global life sciences industry, today announced…

Read More

eRegulatory Binder Checklist: What Does The FDA Require?

01/13/2021

Excerpt from the Article: eRegulatory binders help clinical sites organize and digitize the regulatory process. In this post, we take a brief look at what every FDA-regulated binder needs to have. As a research coordinator or administrator, you’re responsible for managing forms, signatures, monitor visits, regulatory documentation and more. Not to mention squeezing in patient-related…

Read More

AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company’s Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies

01/12/2021

Excerpt from the Press Release: SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has released a preprint of its manuscript describing the development of ImmunoPass, the Company’s rapid point-of-care test that semi-quantitatively…

Read More

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

01/12/2021

Excerpt from the Press Release: DURHAM, NC, USA I January 8, 2021 I Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead…

Read More

NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial

01/11/2021

Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Jan. 11, 2021 /PRNewswire/ — NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) (“Relief”), and the Quantum Leap Healthcare Collaborative (“Quantum Leap”) of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ (RLF-100TM: aviptadil) in the I-SPY COVID-19 Clinical…

Read More

Investigating mental and physical disorders associated with COVID-19 in online health forums

01/08/2021

Excerpt from the Study Abstract: Mebomine – Clinical Insights From Online Patient Communities Objectives Online health forums provide rich and untapped real-time data on population health. Through novel data extraction and natural language processing (NLP) techniques, we characterise the evolution of mental and physical health concerns relating to the COVID-19 pandemic among online health forum…

Read More

Partnering to Educate the Latino Community about COVID-19

01/08/2021

Excerpt from the Article To encourage collaboration among its chapters, the Northeast Regional Board of the Latino Medical Student Association (LMSA) recently tasked chapters in various cities to work together to develop and implement a community service project for their local Latino community. “Our group included Jefferson, Penn, Drexel, PCOM and Temple,” says second-year Temple…

Read More

Two more life-saving Covid drugs discovered

01/07/2021

Excerpt from the Article: Two more life-saving drugs have been found that can cut deaths by a quarter in patients who are sickest with Covid. The anti-inflammatory medications, given via a drip, save an extra life for every 12 treated, say researchers who have carried out a trial in NHS intensive care units. Supplies are…

Read More

AIM ImmunoTech announces first COVID-19-induced chronic fatigue ‘Long Hauler’ patient dosed with Ampligen

01/07/2021

Excerpt from the Article: AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has announced Wednesday that the active AMP-511 Expanded Access Program (EAP) has dosed its first coronavirus (COVID-19) “Long Hauler” patient with the drug Ampligen (rintatolimod).  The company said the initial dosing marks a significant milestone in its efforts to develop an effective therapeutic for people suffering…

Read More

How mRNA went from a scientific backwater to a pandemic crusher

01/07/2021

Excerpt from the Article: In 1995, Katalin Karikó was at her lowest ebb. A biochemist at the University of Pennsylvania (UPenn), Karikó had dedicated much of the previous two decades to finding a way to turn one of the most fundamental building blocks of life, mRNA, into a whole new category of therapeutics. More often…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives